Keri Harris, MD
Adolescent Medicine · Carey, OHNPI 1265487714
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 49 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 22.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $277 and has fallen 59.6% since, to $112 in 2025.
Across 49 payments — averaging $16.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$178
- AbbVie$118
- Novo Nordisk$99
- Lilly USA, LLC$86
- Amgen$85
- Merck$58
- plus $166 from 8 others
What the payments were for
- Food & beverage$790100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 12 | $178 |
| AbbVie | 5 | $118 |
| Novo Nordisk | 7 | $99 |
| Lilly USA, LLC | 5 | $86 |
| Amgen | 6 | $85 |
| Merck | 3 | $58 |
| Sanofi Pasteur Inc. | 2 | $32 |
| Pfizer | 2 | $31 |
| Boehringer Ingelheim | 2 | $30 |
| GSK | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Mannkind Corporation | 1 | $14 |
| Cranial Technologies, Inc | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
How this compares
$790 in reported general payments places this provider in the 65th percentile of 58 adolescent medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 62 | $83,375 |
| JardianceEmpagliflozin | 30 | $49,939 |
| TrulicityDulaglutide | 41 | $38,315 |
| EliquisApixaban | 11 | $11,530 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 17 | $5,842 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 16 | $5,576 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $5,450 |
| Arnuity ElliptaFluticasone Furoate | 12 | $3,379 |
| Levothyroxine Sodium | 239 | $2,189 |
| Rosuvastatin Calcium | 196 | $2,057 |
| Atorvastatin Calcium | 282 | $1,789 |
| Ezetimibe | 66 | $1,753 |
| Metoprolol Succinate | 127 | $1,730 |
| Propranolol Hcl ErPropranolol Hcl | 16 | $1,602 |
| Losartan Potassium | 181 | $1,465 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $99 | $83,37562 claims |
| Boehringer IngelheimJardiance | $30 | $49,93930 claims |
| Lilly USA, LLCTrulicity | $86 | $38,31541 claims |
| PfizerEliquis | $31 | $11,53011 claims |
| GSKArnuity Ellipta | $17 | $3,37912 claims |
| AbbVieSynthroid | $118 | $52833 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 58 adolescent medicine providers in Ohio.
Other adolescent medicine in Carey
- Elise BerlanColumbus$36K
- Nicole BaldwinCincinnati$24K
- David RoerDayton$19K
- Jessica KahnCincinnati$11K
- Kevin HorvathTipp City$7K
- Darcey ThorntonCincinnati$6K
- Veronica IssacCleveland$3K
- Tracy WickDayton$3K
- Stephen SondikeAkron$3K
- Virgie QuePort Clinton$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.